Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
Status:
Active, not recruiting
Trial end date:
2025-03-11
Target enrollment:
Participant gender:
Summary
This study is to find out if an investigational drug called Durvalumab (MEDI4736) given
together with a standard of care aromatase inhibitor drug can help people with breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute